Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eli Lilly and Co LLY

Healthcare Biotechnology
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:LLY)

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

PR Newswire 8 hours ago

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

PR Newswire 1 day ago

Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

PR Newswire 2 days ago

Lilly to participate in J.P. Morgan Healthcare Conference

PR Newswire 8 days ago

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

PR Newswire December 20, 2024

Lilly's Kisunla(TM) (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

PR Newswire December 17, 2024

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

PR Newswire December 17, 2024

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

PR Newswire December 13, 2024

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

PR Newswire December 11, 2024
View More News ››

Opinion & Analysis (NYSE:LLY)

Morning Market Outlook for June 11, 2024

TheUpTrend June 11, 2024

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Streetwise Reports June 17, 2020

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017

The ProMIS of an Alzheimer's cure

The Life Sciences Report May 4, 2017

Diffusion Pharmaceuticals takes aim at brain cancer: CEO David Kalergis

The Life Sciences Report April 1, 2016

The next leg of the health care boom is under way

Dr. David Eifrig June 15, 2015
View More Opinion ››

Bullboard Posts (NYSE:LLY)

Lilly's muvalaplin lowered lipoprotein(a) levels in adults w

Just In: $LLY Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at...
whytestocks - November 18, 2024

Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Yea

BREAKING NEWS: $LLY Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now2024-11-17 06:42:00 ET Tesla (NASDAQ...
whytestocks - November 17, 2024

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical

News; $LLY A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years2024-10-30 04...
whytestocks - October 30, 2024

Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever

JUST IN: $LLY Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever2024-09-28 05:15:00 ET In the stock market, ups and downs are...
whytestocks - September 28, 2024

Think Eli Lilly Stock Has Peaked? These 10 Words From the CE

News; $LLY Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind2024-08-30 07:45:00 ET Eli Lilly (NYSE: LLY...
whytestocks - August 30, 2024

Why Eli Lilly Topped the Market on Tuesday

NEWS: $LLY Why Eli Lilly Topped the Market on Tuesday2024-08-20 16:46:42 ET The U.S. pharmaceutical stock of the moment, Eli Lilly (NYSE...
whytestocks - August 20, 2024
View more Bullboard ››

NexTech3D.AI Corp.

NexTech3D.AI Corp.

NexTech3D.AI Corp. is a diversified augmented reality (AR), artificial intelligence (AI) technology company. The Company ...
View More »